Targeting SARS-CoV-2 main protease for treatment of COVID-19: covalent inhibitors structure–activity relationship insights and evolution perspectives
The viral main protease is one of the most attractive targets among all key enzymes involved
in the SARS-CoV-2 life cycle. Covalent inhibition of the cysteine145 of SARS-CoV-2 MPRO …
in the SARS-CoV-2 life cycle. Covalent inhibition of the cysteine145 of SARS-CoV-2 MPRO …
Drug repurposing for COVID-19: Approaches, challenges and promising candidates
YL Ng, CK Salim, JJH Chu - Pharmacology & therapeutics, 2021 - Elsevier
Traditional drug development and discovery has not kept pace with threats from emerging
and re-emerging diseases such as Ebola virus, MERS-CoV and more recently, SARS-CoV …
and re-emerging diseases such as Ebola virus, MERS-CoV and more recently, SARS-CoV …
Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis
Abstract The coronavirus disease 2019 (COVID-19) pandemic has become a global health
crisis. Considering the recent food and drug administration (FDA) approval of remdesivir as …
crisis. Considering the recent food and drug administration (FDA) approval of remdesivir as …
Baicalein and baicalin inhibit SARS-CoV-2 RNA-dependent-RNA polymerase
Coronavirus Disease 2019 (COVID-19) is a deadly emerging infectious disease caused by
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Because SARS-CoV-2 …
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Because SARS-CoV-2 …
Accelerating COVID-19 research using molecular dynamics simulation
The COVID-19 pandemic has emerged as a global medico-socio-economic disaster. Given
the lack of effective therapeutics against SARS-CoV-2, scientists are racing to disseminate …
the lack of effective therapeutics against SARS-CoV-2, scientists are racing to disseminate …
Computational molecular docking and virtual screening revealed promising SARS-CoV-2 drugs
The pandemic of novel coronavirus disease 2019 (COVID-19) has rampaged the world, with
more than 58.4 million confirmed cases and over 1.38 million deaths across the world by 23 …
more than 58.4 million confirmed cases and over 1.38 million deaths across the world by 23 …
Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants
J Cho, Y Shin, JS Yang, JW Kim, KC Kim, JY Lee - Antiviral research, 2023 - Elsevier
Ongoing emergence of SARS-CoV-2 Omicron subvariants and their rapid worldwide spread
pose a threat to public health. From November 2022 to February 2023, newly emerged …
pose a threat to public health. From November 2022 to February 2023, newly emerged …
Potency of Xanthone Derivatives from Garcinia mangostana L. for COVID-19 Treatment through Angiotensin-Converting Enzyme 2 and Main Protease Blockade: A …
C Suhandi, SS Alfathonah, AN Hasanah - Molecules, 2023 - mdpi.com
ACE2 and Mpro in the pathology of SARS-CoV-2 show great potential in developing COVID-
19 drugs as therapeutic targets, due to their roles as the “gate” of viral entry and viral …
19 drugs as therapeutic targets, due to their roles as the “gate” of viral entry and viral …
RNA dependent RNA polymerase (RdRp) as a drug target for SARS-CoV2
A Mishra, AS Rathore - Journal of Biomolecular Structure and …, 2022 - Taylor & Francis
RNA-dependent RNA polymerase (RdRp), also called nsp12, is considered a promising but
challenging drug target for inhibiting replication and hence, the growth of various RNA …
challenging drug target for inhibiting replication and hence, the growth of various RNA …
Remdesivir strongly binds to RNA-dependent RNA polymerase, membrane protein, and main protease of SARS-CoV-2: indication from molecular modeling and …
Development of new drugs is a time-taking and expensive process. Comprehensive efforts
are being made globally toward the search of therapeutics against SARS-CoV-2. Several …
are being made globally toward the search of therapeutics against SARS-CoV-2. Several …